0
0
Home > Pharmaceuticals >  COVID-19 >  Coronavirus Disease 2019 (COVID-19) Analyst Consensus Global Drug Sales Forecast – Q3, 2021

Coronavirus Disease 2019 (COVID-19) Analyst Consensus Global Drug Sales Forecast – Q3, 2021

This report contains a summary of the analyst consensus forecasts available in the GlobalData Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Currently there are 41 drugs indicated for COVID-19 which have analyst consensus forecasts available.

Scope

This 43-page report gives important, expert insight you won’t find in any other source. 16 figures throughout the report illustrate major points and trends in COVID sales forecasts and company pipelines. This report is required reading for:

Investors that want to understand how COVID-19 has impacted Drug Revenues in the biopharmaceutical industry as well as identifying companies to invest in

Companies that are interested in entering the COVID-19 disease space

Large pharma companies with investment groups or BD teams looking for partnership opportunities in the COVID-19 disease space

Reasons to buy

Analysis of COVID-19 analyst consensus sales forecasts

Overview of Pipeline portfolio of companies involved in COVID-19 disease space

Detailed Analysis of how COVID-19 have affected analyst consensus sales forecasts for previously forecasted Drugs

Companies mentioned

Arcturus Therapeutics Ltd

Atossa Therapeutics Inc

CanSino Biologics Inc

ContraFect Corp

CTI BioPharma Corp

CureVac NV

Dynavax Technologies Corp

Eiger BioPharmaceuticals Inc

Eli Lilly and Co

Enlivex Therapeutics Ltd

Evelo Biosciences Inc

Genexine Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Heat Biologics Inc

I-Mab

Immunome Inc

InflaRx NV

Inovio Pharmaceuticals Inc

Kiniksa Pharmaceuticals Ltd

Moderna Inc

Molecular Partners AG

Novavax Inc

Pfizer Inc

Regeneron Pharmaceuticals Inc

Shionogi & Co Ltd

TFF Pharmaceuticals Inc

Vir Biotechnology Inc

Table of Contents

1 COVID-19 Global Analyst Consensus Sales Forecast

1.1 COVID-19 Prophylactic Vaccines with Global Analyst Consensus Sales Forecast

1.2 COVID-19 Therapeutic Drugs with Global Analyst Consensus Sales Forecast

1.3 COVID-19 Global Analyst Consensus Sales Forecast

1.4 Top Three COVID-19 Drugs with Peak Forecast: Global Analyst Consensus Sales Forecast

2 COVID-19 Prophylactic Vaccine and Therapeutic Drugs: Global Analyst Consensus Sales Forecasts

2.1 COVID-19 Prophylactic Vaccine Global Analyst Consensus Sales Forecast

2.2 COVID-19 Therapeutic Drugs: Global Analyst Consensus Sales Forecast

3 BioNTech SE

3.1 Global Analyst Consensus Sales Forecast – Comirnaty

3.2 Percentage Change from Q2 2021 to Q3 2021 Global Analyst Consensus Sales Forecast- Comirnaty

4 Moderna

4.1 Global Analyst Consensus Sales Forecast – mRNA-1273

4.2 Percentage Change from Q2 2021 to Q3 2021 Global Analyst Consensus Sales Forecast – mRNA-1273

5 Cansino Biologics Inc

5.1 Global Analyst Consensus Sales Forecast – Convidecia

5.2 Percentage Change from Q2 2021 to Q3 2021 Global Analyst Consensus Sales Forecast – Convidecia

6 Johnson & Johnson

6.1 Global Analyst Consensus Sales Forecast – COVID-19 Vaccine 

6.2 Percentage Change from Q2 2021 to Q3 2021 Global Analyst Consensus Sales Forecast – COVID-19 Vaccine 

7 Gilead Sciences

7.1 Global Analyst Consensus Sales Forecast – Veklury

7.2 Percentage Change from Q2 2021 to Q3 2021 Global Analyst Consensus Sales Forecast – Veklury

8 Key Findings

9 Appendix

9.1 Abbreviations

9.2 Methodology

9.3 Related Reports

9.4 About the Authors

9.5 About GlobalData

9.6 Contact Us

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports